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OBJECTIVE—Insulin resistance and type 2 diabetes are asso-
ciated with an atherogenic lipoprotein profile. We examined the
role of visceral and subcutaneous fat depots, independent of
BMI, on the dyslipidemia associated with type 2 diabetes.
RESEARCH DESIGN AND METHODS— A total of 382 sub-
jects with type 2 diabetes underwent abdominal computed
tomography to evaluate subcutaneous (SAT) and visceral adi-
pose tissue (VAT) distribution and had anthropometric measure-
ments to determine BMI and waist and hip circumference.
Fasting blood was obtained for lipoprotein particle number and
size using nuclear magnetic resonance spectroscopy. The rela-
tionship of lipoprotein particle number and size with BMI, SAT,
and VAT was examined using multivariable regression models
adjusted for age, sex, diabetes therapy, duration of diabetes,
smoking, statin use, and A1C levels. The relation of VAT to
lipoprotein particle number and size was further evaluated after
the addition of BMI, BMI plus SAT, or BMI plus homeostatis is
model assessment of insulin resistance (HOMA-IR) to the model.
RESULTS—VAT was positively related to VLDL particle number
(P  0.0001), LDL particle number (P  0.01), and VLDL size
(P  0.0001) and negatively related to LDL size (P  0.0001) and
HDL size (P  0.0001). These relationships remained unchanged
after addition of BMI and SAT to the model. After addition of
HOMA-IR, VAT remained positively related to VLDL particle
number (P  0.0001) and size (P  0.01) and negatively related
to LDL and HDL particle size (P  0.0001 for both comparisons).
Neither BMI nor SAT was independently related to lipoprotein
parameters.
CONCLUSIONS—In patients with type 2 diabetes, higher VAT
independent of BMI was associated with higher VLDL and LDL
particle number, larger VLDL particles, and smaller LDL and HDL
particles. This lipoprotein pattern has been associated with
increased risk for atherosclerosis and cardiovascular disease.
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Dyslipidemia and increased adiposity, especiallyof abdominal type, are common metabolic fea-tures of type 2 diabetes. The dyslipidemia as-sociated with type 2 diabetes is characterized
by changes in lipoprotein particle number and size and
has been attributed to insulin resistance (1,2). Studies us-
ing nuclear magnetic resonance (NMR) spectroscopy to
analyze lipoprotein subclass profile along with euglycemic-
hyperinsulinemic clamps (1) or frequently sampled in-
travenous glucose tolerance tests (2) to assess insulin
sensitivity have clearly demonstrated that all three major
human lipoproteins are affected by insulin resistance. The
alterations in lipoprotein particle number and size in type
2 diabetes and insulin resistance have been linked to
increased risk for cardiovascular disease (CVD) in both
cross-sectional (3–9) and prospective studies (10,11).
Obesity has been clearly demonstrated to be associated
with insulin resistance and its metabolic consequences,
including type 2 diabetes, dyslipidemia, and CVD (12–14).
Recently, studies have suggested that fat tissue distri-
bution may be more important than overall fat mass for
these associations (15–17). Epidemiologic and physio-
logic studies have suggested that abdominal fat is more
strongly associated with metabolic risk factors and CVD
than total amount of body fat (15,16,18). Whether specific
abdominal fat compartments—for example, visceral ab-
dominal fat (VAT) compared with subcutaneous abdomi-
nal fat (SAT)—carry greater metabolic and cardiovascular
risks remains more controversial (16,17), especially in
subjects with type 2 diabetes (17). Even though many
studies have pointed to a greater cardiovascular and
metabolic risk associated with VAT (18–27), SAT has also
been associated with insulin resistance and metabolic
disorders in other studies (27–30). For this report, we
examined the association between abdominal fat com-
partments measured by computed tomography (CT) and
lipoprotein particle number and size using NMR spectros-
copy in 382 subjects with type 2 diabetes who participated
in the CHICAGO study (31). We further analyzed how the
relationship of abdominal fat depots to lipoprotein param-
eters was impacted by BMI as a measure of overall
adiposity or by hip circumference as an index of periph-
eral subcutaneous fat mass.
RESEARCH DESIGN AND METHODS
Subjects for the current analysis were Caucasian and African-American
participants in the CHICAGO trial, a prospective study of the effects of
pioglitazone compared with glimepiride on carotid intima-media thickness in
subjects with type 2 diabetes recruited from 28 clinical sites in Chicago (31).
The details of the study have been previously reported (31,32). Data included
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in this report were obtained before randomization to treatment groups. All
subjects were asymptomatic for coronary artery disease at baseline. The study
was approved by central and local institutional review board committees, and
all participants provided written informed consent. All subjects underwent
measurements of height, weight, and waist and hip circumference by a trained
nurse at the baseline visit. Waist circumference was measured at the smallest
circumference between the ribs and iliac crest, and hip circumference was
measured at maximum circumference between the iliac crest and crotch to
the nearest 0.1 cm. BMI was calculated as weight in kilograms divided by the
square of height in meters.
Subjects underwent an abdominal CT scan for determination of VAT and
SAT. Abdominal adipose tissue content and distribution were quantified by CT
scan at the level of L4-L5 vertebra when subjects were in supine position with
both arms stretched above the head (33–35). A single 6-mm slice was taken
during suspended respiration after a normal expiration. Total abdominal
adipose tissue (TAT) area was measured by delineating the body surface with
a receiver operator instrument (ROI) and then computing the adipose tissue
volume using an attenuation range of 190 to 30 HU (33–35). VAT area was
quantified by delineating the abdominal cavity at the internal aspect of the
abdominal wall and the posterior aspect of the vertebral body with an ROI
(33–35). SAT was calculated by subtracting VAT from TAT area. To obtain
VAT and SAT volumes, the area for each fat component was multiplied by the
slice thickness. Fasting blood samples were obtained at the baseline visit for
measurement of lipids, A1C, and lipoprotein profile (31,32). Lipoproteins were
analyzed using NMR technology by LipoScience (Raleigh, NC) (1).
Statistical methods. Homeostatis model assessment insulin resistance
(HOMA-IR) was calculated according to the following formula: [fasting glucose
(mmol/l)  fasting insulin (U/ml)]/22.5. Log transformation of the data was
performed when necessary to achieve homogeneity of variance. Pearson
correlation coefficients were used after adjustment for age and sex to assess
the relationship between each subclass lipoprotein particle number and size
and BMI, waist circumference, A1C, SAT, and VAT. Each subclass lipoprotein
particle number and size was further examined in relation to BMI, SAT, and
VAT areas using a general linear model with sex, statin use, and diabetes
therapy as fixed variables and age, duration of diabetes, years of smoking, and
A1C levels as continuous variables. The multivariable analyses were repeated
with the addition of BMI to the models when assessing the relation of VAT or
SAT to lipoprotein number and size or with the addition of both VAT and SAT
to the model when assessing the relation of BMI to lipoprotein parameters. To
evaluate the impact of insulin resistance on these relationships, HOMA-IR was
further added to the models. The associations between VAT and lipoprotein
particle number and size were further examined by multivariable models after
addition of SAT or of hip circumference to models that included BMI. Similar
analyses were performed to evaluate the association of SAT to lipoprotein
parameters before and after adjustment for BMI or for BMI and VAT. Analyses
were performed for the entire group and then separately for statin-treated and
untreated subjects. The relation of A1C to BMI, VAT, and SAT was examined
using a general linear model with sex, statin use, and diabetes therapy as fixed
variables and age, duration of diabetes, and years of smoking as continuous
variables. Additional models were performed after the addition of BMI and
BMI plus VAT and SAT. General linear modeling was also used to examine the
relation of non-HDL cholesterol to BMI, VAT, and SAT areas with sex, statin
use, and diabetes therapy as fixed variables and age, duration of diabetes,
years of smoking, and A1C levels as continuous variables. Analyses were
performed using the 11.0 PC package of SPSS statistical software (SPSS,
Chicago, IL). A P  0.01 was considered significant to adjust for evaluation of
multiple lipoprotein parameters (VLDL, LDL, and HDL particle number and
size) for their relation to VAT (which was our primary analysis) and other
adiposity measures (as secondary analyses).
RESULTS
The baseline characteristics of study subjects are pre-
sented in Table 1. The mean age was 61 years. Thirty-eight
percent of subjects were women, 55% were on statin
therapy, and 65% were current or former smokers. Sub-
jects were on the following diabetes therapies at the time
of participation in the study: 15% of subjects were not
taking any medications for diabetes, 15% were taking
sulfonylureas alone, 29% were taking metformin alone,
31% were taking a combination of metformin and sulfon-
lyureas, and 10% were on insulin therapy. The average BMI
was 32.5 kg/m2, the mean duration of type 2 diabetes was
92 months, and the mean A1C was 7.4%. Mean HDL
cholesterol was 1.2 nmol/l, LDL cholesterol 2.8 nmol/l, and
triglyceride 1.8 nmol/l. In age- and sex-adjusted correla-
tions, VAT was positively associated with VLDL particle
number, LDL particle number, and VLDL size and nega-
tively associated with LDL size and HDL size (Table 2).
BMI and SAT were not associated with particle size or
number for any lipoprotein species (Table 2). Waist cir-
cumference was negatively associated with LDL and HDL
size. A1C was positively associated with VLDL and LDL
particle number and negatively associated with LDL size
(Table 2).
The results from multivariable regression models are
TABLE 1
Baseline characteristics of study participants
Subjects with type 2 diabetes (n) 382
Age (years) 61 8
BMI (kg/m2) 32.5 5.1
Waist (cm) 108 13
Hip (cm) 113 12
Sex (%)
Men 62
Women 38
Statin use (%)
On statin 55
No statin 45
Smoking (%)
Current 16
Former 49
Never 35
Duration of type 2 diabetes (months) 92 86
Diabetes therapy (%)
None 15
Sulfonylurea 15
Metformin 29
Sulfonylurea and metformin 31
Insulin 10
A1C (%) 7.4  0.9
Total cholesterol (nmol/l) 4.7 0.9
LDL cholesterol (nmol/l) 2.8 0.8
HDL cholesterol (nmol/l) 1.2 0.3
Triglyceride (nmol/l) 1.9 1.3
VLDL number (nmol/l) 70.12 49.91
LDL number (nmol/l) 1,440.56 422.33
HDL number (nmol/l) 31.89 6.44
VLDL size (nm) 52.83 10.18
LDL size (nm) 20.52 0.78
HDL size (nm) 8.61 0.38
VAT (cm3) 132.0 56.8
SAT (cm3) 196.3 80.2
Data for continuous variables are presented as means  SD.
TABLE 2
Age- and sex-adjusted Pearson correlation coefficients between
log-transformed lipoprotein particle size and number and BMI,
waist circumference, VAT, SAT, and A1C
Variable BMI Waist VAT SAT A1C
Particle no.
VLDL 0.11 0.13 0.34* 0.04 0.14†
LDL 0.04 0.08 0.15* 0.002 0.13†
HDL 0.10 0.06 0.04 0.04 0.05
Size
VLDL 0.05 0.02 0.25* 0.06 0.05
LDL 0.07 0.16* 0.34* 0.005 0.17*
HDL 0.08 0.16* 0.30* 0.02 0.06
*P  0.001; †P  0.01.
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shown in Table 3. After adjustment for age, sex, diabetes
therapy, duration of diabetes, statin use, A1C, and smoking
years, VAT was positively associated with VLDL and LDL
particle number and VLDL particle size and negatively
associated with LDL and HDL size. These associations
remained significant after adjustment for BMI. Addition of
SAT with BMI to the model did not change the strength of
the associations (data not shown). SAT was not associated
with lipoprotein particle size or number before or after
adjustment for BMI (Table 3) or after adjustment for BMI
and VAT (data not shown). BMI was borderline associated
with VLDL and HDL particle number, and the borderline
association with HDL particle number persisted after
adjustment for SAT and VAT (Table 3). Addition of
HOMA-IR did not change the associations between VAT
and VLDL particle number or size or VAT and LDL or HDL
size (Table 4).
It has been suggested that lower-body subcutaneous fat
may have beneficial effects on insulin sensitivity and
cardiometabolic risk. We therefore added hip circumfer-
ence, as an index of lower-body subcutaneous fat mass, to
the multivariable model for the relationship of VAT to
lipoprotein particle number and size. After addition of hip
circumference to the multivariable model, we noted a
4–10% increase in regression coefficient for the models
examining the relation between VAT and each lipoprotein
particle number and size (data not shown).
Because of the potent effect of statins on lipoprotein
metabolism, we assessed the relationship between VAT
and lipoprotein parameters in statin users and nonusers
separately (Table 5). The association between VAT and
LDL particle number was only present among statin non-
users, but VAT was strongly and significantly related to
VLDL particle number and size and LDL and HDL particle
size among statin users (Table 5).
The data in Table 2 show that glycohemoglobin level
was significantly associated with VLDL and LDL particle
number and LDL size. After adjustment for age, sex,
baseline diabetes therapy, duration of diabetes, smoking
years, and statin use, A1C level remained positively asso-
ciated with VLDL particle number and LDL particle num-
ber and negatively associated with LDL particle size.
These significant associations remained intact after addi-
tion of BMI or after addition of BMI, VAT, and SAT to the
model (data not shown). In multivariable models, neither
BMI nor SAT was a significant predictor of non-HDL
cholesterol (not shown). VAT had a borderline significant
association with non-HDL cholesterol; P  0.02, r 2 
0.15, 0.03 (0.02–0.04) mmol/l increase for each 10 cm3
increase in VAT.
DISCUSSION
In this population of middle- and older-aged men and
women with type 2 diabetes, higher VAT was strongly
associated with changes in lipoprotein particle number
and size (1,2). These associations were independent of
overall adiposity as measured by BMI and were indepen-
dent of SAT content. The associations persisted after
adjustment for HOMA-IR as a measure of insulin resis-
TABLE 3
Multivariable-adjusted linear regression models for relation of SAT, VAT, or BMI to lipoprotein particle number and size
Multivariable model*
Multivariable model with SAT or VAT
adjusted for BMI or with BMI adjusted for
both SAT and VAT
r2
Change in
lipoprotein size
or number† P value r2
Change in
lipoprotein size
or number† P value
VLDL particle no. (nmol/l)
SAT 0.10 1.14 (1.29 to 1.68) 0.50 0.12 1.09 (1.67 to 1.40) 0.7
VAT 0.20 4.25 (2.74–6.69) 0.0001 0.20 4.58 (2.75–7.64) 0.0001
BMI 0.10 0.47 (0.13–1.66) 0.02 0.20 0.11 (0.65 to 0.51) 0.9
LDL particle no. (nmol/l)
SAT 0.12 1.02 (1.29 to 1.68) 0.50 0.12 1.09 (1.67 to 1.40) 0.7
VAT 0.14 1.29 (1.08–1.53) 0.004 0.14 1.29 (1.06–1.58) 0.01
BMI 0.12 0.13 (0.12 to 0.21) 0.3 0.15 0.11 (0.18 to 0.22) 0.7
HDL particle no. nmol/l
SAT 0.15 1.00 (1.10 to 1.10) 0.9 0.17 1.07 (1.04 to 1.19) 0.3
VAT 0.14 1.06 (1.20 to 1.061) 0.3 0.15 1.02 (1.13 to 1.17) 0.8
BMI 0.15 0.15 (0.20 to0.11) 0.02 0.17 0.17 (0.27 to0.11) 0.02
VLDL size (nm)
SAT 0.14 1.05 (1.15 to 1.04) 0.30 0.14 1.08 (1.19 to 1.03) 0.2
VAT 0.17 1.24 (1.11–1.38) 0.0001 0.17 1.32 (1.16–1.49) 0.0001
BMI 0.13 0.11 (0.13 to 0.14) 0.7 0.18 0.12 (0.18 to 0.13) 0.4
LDL size (nm)
SAT 0.21 1.01 (1.01 to 1.02) 0.8 0.22 1.01 (1.01 to 1.03) 0.3
VAT 0.29 1.06 (1.08 to1.04) 0.0001 0.29 1.07 (1.10 to1.05) 0.0001
BMI 0.22 0.10 (0.11 to 0.10) 0.31 0.31 0.10 (0.11 to 0.11) 0.6
HDL size (nm)
SAT 0.19 1.00 (1.02 to 1.02) 0.9 0.21 1.01 (1.01 to 1.04) 0.3
VAT 0.26 1.07 (1.10 to1.05) 0.0001 0.26 1.08 (1.11 to1.05) 0.0001
BMI 0.19 0.11 (0.11 to 0.10) 0.1 0.31 0.10 (0.11 to 0.11) 0.6
*Multivariable model is adjusted for age, sex, diabetes therapy at baseline, duration of diabetes, years of smoking, statin use, and A1C.
†Change in variable for every 10 cm3 increase in VAT or SAT or every 1 kg/m2 increase in BMI.
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tance for all of the lipoprotein parameters except for LDL
particle number. The associations were strongest in sub-
jects who were not on statin therapy but remained signif-
icant for VLDL particle number and size and LDL and HDL
size in subjects who were treated with statins. We did not
observe associations between SAT and lipoprotein particle
number or size. We observed a borderline negative asso-
ciation between BMI and HDL particle number, as higher
BMI was associated with a decrease in HDL particle
number. Our data suggest that in type 2 diabetes, adverse
changes in lipoprotein particle number and size are most
strongly related to accumulation of visceral fat rather than
overall adiposity.
Whereas the harmful impact of central fat on insulin
sensitivity and metabolic disorders is well accepted (15),
the individual contribution of VAT and SAT to metabolic
risk remains uncertain (15–17). Visceral fat is considered
to have greater lipolytic activity compared with subcuta-
neous fat and has favored access to the liver through the
portal vein. Thus, it has been proposed that the high free
fatty acid (FFA) flux from visceral fat may reduce hepatic
insulin sensitivity, favor hepatic fat accumulation, and
thereby promote an atherogenic lipid profile (36). How-
ever, a number of studies have suggested that SAT may
have as strong or even stronger deleterious impact on
insulin sensitivity and metabolic risk than VAT (28–30,37).
SAT comprises a larger fat depot than visceral fat (38) and
contributes 75% of the total FFA to the peripheral
circulation (39,40). Other studies have suggested a less
important role for SAT compared with VAT (20,27,41). In a
recent report, surgical removal of SAT in obese subjects
did not result in metabolic improvements or beneficial
changes in cardiovascular risk factors (42). In our study,
SAT was not associated with the changes in lipoprotein
particle size or number typically observed with insulin
resistance. Unlike most previous studies, however, our
study focused exclusively on subjects with type 2 diabetes,
a large proportion of whom were obese (20,27–29). The
relationship between central fat depots and metabolic risk
could be modified in diabetes either by the more severe
degree of insulin resistance in type 2 diabetic compared
with obese nondiabetic subjects or by the failure of insulin
secretion to compensate for the metabolic derangements
produced by insulin resistance (43,44). Increasing evi-
dence indicates that adipose tissue, especially VAT, is the
source of a number of hormones (45), cytokines, and
inflammatory factors (46) that can impact substrate flux
and lipid metabolism in distant tissues. It is possible that
this secretory pattern is altered by the presence of type 2
diabetes (47). Recently, an association between small LDL
particles and plasminogen activator inhibitor-1 in subjects
with type 2 diabetes has been shown to be related to VAT
(48).
The role of adipose tissue distribution in insulin sensi-
tivity and metabolic risk extends beyond abdominal fat.
Increases in hepatic and skeletal muscle fat have also been
associated with insulin resistance (30,49). Furthermore,
lower body fat has been shown to at least partially
TABLE 4
Multivariable-adjusted linear regression model for relation of VAT to lipoprotein particle number and size before and after adjustment
for HOMA-IR
Multivariable model plus BMI* Multivariable model plus BMI and HOMA-IR*
r2
Change in
lipoprotein size
or number† P value r2
Change in
lipoprotein size
or number† P value
Particle no. (nmol/l)
VLDL 0.2 4.56 (2.51–8.28) 0.0001 0.23 3.94 (2.31–6.75) 0.0001
LDL 0.14 1.29 (1.06–1.58) 0.01 0.14 1.23 (1.00 to 1.53) 0.06
Size (nm)
VLDL 0.17 1.32 (1.16–1.49) 0.0001 0.21 1.23 (1.08–1.40) 0.002
LDL 0.29 1.07 (1.10 to 1.05) 0.0001 0.31 1.06 (1.09 to1.04) 0.0001
HDL 0.26 1.08 (1.11 to 1.05) 0.0001 0.29 1.07 (1.10 to1.04) 0.0001
*Multivariable model is adjusted for age, sex, diabetes therapy, duration of diabetes, years of smoking, statin use, and A1C. †Increase in
variable for every 10 cm3 increase in VAT.
TABLE 5
Multivariable-adjusted linear regression models for relation of
VAT to lipoprotein particle number or size after adjustment for
BMI for the overall group and separately for statin users and
nonusers
Model r2*
Change in
lipoprotein size
or number† P value
VLDL particle no.
(nmol/l)
Overall 0.20 4.58 (2.75–7.64) 0.0001
Statin 0.18 3.72 (1.86–7.46) 0.0001
No statin 0.25 5.87 (2.70–12.7) 0.0001
LDL particle no.
(nmol/l)
Overall 0.14 1.29 (1.06–1.58) 0.01
Statin 0.09 1.12 (1.16 to 1.47) 0.38
No statin 0.18 1.49 (1.09–2.04) 0.01
VLDL size (nm)
Overall 0.17 1.32 (1.16–1.49) 0.0001
Statin 0.20 1.42 (1.19–1.69) 0.0001
No statin 0.15 1.22 (1.02–1.48) 0.03
LDL size (nm)
Overall 0.29 1.07 (1.10 to 1.05) 0.0001
Statin 0.27 1.06 (1.10 to 1.03) 0.0001
No statin 0.29 1.08 (1.12 to 1.04) 0.0001
HDL size (nm)
Overall 0.26 1.08 (1.11 to 1.05) 0.0001
Statin 0.25 1.06 (1.10 to 1.02) 0.0001
No statin 0.29 1.10 (1.15 to 1.06) 0.0001
*Multivariable model for the overall group is adjusted for age, sex,
diabetes therapy at baseline, duration of diabetes, years of smoking,
statin use, and A1C. Multivariable model for statin and no statin
groups is adjusted for age, sex, diabetes therapy at baseline, duration
of diabetes, years of smoking, and A1C. †Increase in variable for
every 10 cm3 increase in VAT.
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counteract the influence of abdominal fat and protect
against insulin resistance (50). Peripheral body fat, mainly
stored in subcutaneous thigh and gluteal regions, has
lower lipolytic activity compared with central fat and may
serve as a metabolic sink by taking up excess circulating
FFA and even preventing ectopic fat accumulation (51).
Recent data indicate that waist and hip circumference
have opposite associations with coronary artery disease;
the risk for developing coronary artery disease increased
with waist circumference, but the risk was lowered by
increasing hip circumference (52). A recent study has
shown that subjects with type 2 diabetes had less leg fat
mass and greater liver and trunk fat mass compared with
similarly obese subjects without type 2 diabetes (30).
Interestingly, in our study adjustment for hip circumfer-
ence in multivariable analyses tended to strengthen the
associations between VAT and atherogenic lipoprotein
particle number and size parameters, suggesting that
higher fat content in the gluteal-femoral area could miti-
gate the negative impact of visceral fat on lipoprotein
metabolism. However, overall changes were small, and we
did not perform imaging studies to quantify lower body fat
depots.
Studies using NMR technology to analyze subclass li-
poprotein profile have demonstrated that progressive in-
sulin resistance is associated with an increase in VLDL size
and large VLDL particle concentration, a decrease in LDL
size reflecting marked increase in small LDL particles and
a reduction in large LDL, an overall increase in the number
of LDL particles, and a decrease in HDL size as a result of
reduction of large HDL particles and a modest increase in
small HDL (1). These alterations in lipoprotein particle
number and size are considered to be atherogenic and to
predispose to CVD (3–11). In this study, we demonstrate
that these unfavorable changes in lipoprotein profile were
related to increasing VAT independent of overall adiposity
or of SAT, suggesting that VAT has serious negative
consequences on lipoprotein metabolism leading to in-
creased risk for CVD in subjects with type 2 diabetes.
Statin therapy abolished the relation between VAT and
LDL particle number but was not able to abolish the
relationship between VAT and VLDL particle number or
between VAT and VLDL, LDL, and HDL particle size. These
data could indicate that statin therapy only partially ad-
dresses lipoprotein-related CVD risk in subjects with type
2 diabetes. Residual excess CVD risk in subjects with
diabetes who have been treated with statins has been
observed (53) and may be addressed by therapies that
impact residual lipoprotein abnormalities. Our data also
emphasize that the adverse effects of VAT on lipoprotein
parameters are not completely reversed by statin therapy,
underlining the importance of interventions that produce
weight loss, particularly in the visceral fat depot.
Strengths of our study include inclusion of a large
sample of well-characterized subjects with type 2 diabetes,
the use of NMR technology for determination of subclass
lipoprotein profile, and the use of CT scanning to quanti-
tate VAT and SAT. We were also able to adjust for a
number of potential confounders, including smoking his-
tory, sex, and statin use. With respect to limitations, our
study does not permit firm conclusions regarding causal-
ity. In addition, we do not have measures of overall
truncal, hepatic, or lower-extremity fat that could have
provided additional information on the association be-
tween body fat distribution and lipoprotein particle num-
ber and size. Our study included only diabetic subjects,
and relationships may be different in those without diabe-
tes. In addition, our subjects had BMIs that clustered in the
obese range, as is typical for type 2 diabetes. The influence
of adipose tissue distribution on lipoprotein parameters
could be different in those with lower BMI.
In summary, increasing VAT independent of BMI and
SAT was associated with an atherogenic lipoprotein pro-
file in subjects with type 2 diabetes. In contrast, in our
study we were unable to show an association between
SAT or BMI and lipoprotein parameters. The data suggest
that the atherogenic lipoprotein profile associated with
type 2 diabetes is related to VAT accumulation. Prospec-
tive studies will be needed to provide more information
regarding the causal nature of these associations.
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